Study Shows Insulin-Producing Cells Able to Regenerate
Posted on: Thursday, 6 May 2004, 06:00 CDT
A new study shows that insulin-producing cells in the pancreas can regenerate themselves, suggesting future treatments for diabetes that could eliminate the need to inject the hormone.
In type 1, or juvenile, diabetes, the body's immune system attacks and destroys a type of specialized cell that makes insulin. The hormone is vital in maintaining the right blood sugar levels.
Regenerating and maintaining these cells in the pancreas could help people with type 1 diabetes make their own insulin. The research does not address the vast majority of diabetes cases, type 2, linked to obesity.
Researchers have been seeking ways to produce more of these specialized insulin-producing cells, called beta cells. The new study, done in laboratory mice, suggests there is no need to look beyond the cells themselves. Details are in today's issue of the journal Nature.
Previous studies have suggested that embryonic stem cells or adult stem cells also could be sources for the insulin-producing cells.
The new research found no evidence that adult stem cells - which some groups have hoped would offer an alternative to human embryos - are involved in the regeneration of the insulin-producing cells.
"That's now been eliminated in my mind and gives us two cell types to concentrate on," said study co-author Douglas Melton, a Howard Hughes Medical Institute researcher at Harvard University.
Other experts disagreed, saying differently designed experiments could reveal that adult stem cells do play a role.
"We need to keep all the options open, absolutely," said Vijay Ramiya, who researches pancreatic beta cells at the University of Florida.
It also remains unclear whether beta cells could replicate themselves in sufficient numbers to be useful.
And coaxing embryonic stem cells into forming new insulin- producers appears difficult too, since the cells tend to form tumorous growths, said David Prentice of Indiana State University and a founder of Do No Harm, a group opposed to the use of embryonic stem cells.
Related Articles
- A Non-Injectable Short-Acting Insulin for Type 1 Diabetes With Significantly Improved Efficacy Over Insulin Aspart Would Earn a Higher Patient Share in Europe Than in the United States
- Reduction in Antibody Gene Rearrangement in B Cells Related to Type 1 Diabetes, Lupus
- MannKind Reports Positive Data From a Phase 3 Clinical Study of Technosphere Insulin in Type 1 Diabetes
- Osiris Therapeutics Announces $2 Million Milestone Payment for Clinical Progress of a Stem Cell Therapy for Type 1 Diabetes
- Alba Therapeutics Announces IND for Beta Cell Preservation in Type 1 Diabetes Using AT-1001
- Effect of Three Months' Treatment With Irbesartan on Blood and Pulse Pressure of Hypertensive Type 2 Diabetic Patients: Open, Observational Study in 31793 Patients
- Differential Association of Basal and Postprandial Plasma Ghrelin With Leptin, Insulin, and Type 2 Diabetes
- Mannose-Binding Lectin As a Predictor of Microalbuminuria in Type 1 Diabetes: An Inception Cohort Study
- The Effect of Irbesartan in Reducing Cardiovascular Risk in Hypertensive Type 2 Diabetic Patients: an Observational Study in 16 600 Patients in Primary Care
- Metabolic Syndrome As a Predictor of All-Cause and Cardiovascular Mortality in Type 2 Diabetes: The Casale Monferrato Study
User Comments (0)

RSS Feeds